John Overdeck’s Alzamend Neuro ALZN Stock Holding History

John Overdeck’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14	Closed	-$10.9K	–	2938
2022 Q4	$10.9K	Buy	+14	New	+$20.3K	﹤0.01%	2727
2021 Q4	–	Sell	-128	Closed	-$533K	–	4228
2021 Q3	$533K	Buy	+128	New	+$703K	﹤0.01%	3197

Other funds holding ALZN

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

John Overdeck's ALZN Position: Q1 2023 in Review

John Overdeck sold out of Alzamend Neuro (ALZN) in Q1 2023, closing a stake of 14 shares — an estimated $10.9K sold.

John Overdeck first reported a position in ALZN in Q3 2021 and held it in 2 quarters. The position peaked at $533K in Q3 2021. 24 funds tracked by Wall St. Rank hold ALZN as of Q1 2023.

John Overdeck reported no remaining Alzamend Neuro position as of Q1 2023 after selling out during the quarter.
John Overdeck sold 14 Alzamend Neuro shares in Q1 2023, an estimated $10.9K.
John Overdeck first reported a position in Alzamend Neuro in Q3 2021 and held it in 2 quarters.
John Overdeck's Alzamend Neuro position peaked at $533K in Q3 2021.
24 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2023.

Based on Two Sigma Investments's 13F filing for Q1 2023, filed 15 May 2023.